Drug Profile
Irinotecan sucrosofate companion diagnostic - Merrimack Pharmaceuticals
Alternative Names: Ferumoxytol - Merrimack Pharmaceuticals; MM-398 companion diagnosticLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Merrimack Pharmaceuticals
- Class Antianaemics; Contrast media; Diagnostic agents; Ferric compounds; Ferrous compounds; Heavy metals; Minerals; Vascular disorder therapies
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Diagnosis) in USA (IV, Infusion)
- 08 Apr 2014 Preliminary efficacy and adverse events data from a phase I pilot study released by Merrimack Pharmaceuticals
- 19 Dec 2012 Phase-I clinical trials in Solid tumours (diagnosis) USA (IV)